EP Patent

EP1971362B1 — Exendin for treating diabetes and reducing body weight

Assigned to Amylin Pharmaceuticals LLC · Expires 2014-12-03 · 11y expired

What this patent protects

Patent listed against null.

Drugs covered by this patent

Patent Metadata

Patent number: EP1971362B1
Jurisdiction: EP
Classification: —
Expires: 2014-12-03
Drug substance claim: No
Drug product claim: No
Assignee: Amylin Pharmaceuticals LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.